Apellis Pharmaceuticals, Inc. $APLS Shares Sold by Wealth Enhancement Advisory Services LLC

by · The Markets Daily

Wealth Enhancement Advisory Services LLC reduced its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 23.0% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 77,508 shares of the company’s stock after selling 23,158 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Apellis Pharmaceuticals were worth $1,754,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Amalgamated Bank grew its stake in shares of Apellis Pharmaceuticals by 6.9% in the third quarter. Amalgamated Bank now owns 8,674 shares of the company’s stock worth $196,000 after acquiring an additional 563 shares in the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in Apellis Pharmaceuticals during the 3rd quarter worth $1,212,000. Lecap Asset Management Ltd. purchased a new stake in Apellis Pharmaceuticals during the 3rd quarter worth about $223,000. SG Americas Securities LLC increased its holdings in Apellis Pharmaceuticals by 825.4% during the 3rd quarter. SG Americas Securities LLC now owns 417,392 shares of the company’s stock worth $9,446,000 after purchasing an additional 372,289 shares during the period. Finally, Financiere des Professionnels Fonds d investissement inc. acquired a new stake in Apellis Pharmaceuticals in the 3rd quarter valued at about $214,000. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. The Goldman Sachs Group reaffirmed a “sell” rating and set a $19.00 price objective on shares of Apellis Pharmaceuticals in a research report on Monday, January 12th. TD Cowen dropped their target price on shares of Apellis Pharmaceuticals from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Friday, October 31st. Cantor Fitzgerald reduced their target price on Apellis Pharmaceuticals from $39.00 to $35.00 and set an “overweight” rating for the company in a report on Tuesday, January 13th. Weiss Ratings reissued a “sell (d)” rating on shares of Apellis Pharmaceuticals in a research report on Monday, December 29th. Finally, Citigroup cut their price target on Apellis Pharmaceuticals from $52.00 to $45.00 and set a “buy” rating on the stock in a research report on Friday, October 31st. Twelve research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Apellis Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $33.00.

View Our Latest Stock Analysis on APLS

Apellis Pharmaceuticals Price Performance

APLS opened at $22.58 on Friday. Apellis Pharmaceuticals, Inc. has a 1 year low of $16.10 and a 1 year high of $30.60. The company’s 50 day simple moving average is $23.30 and its 200 day simple moving average is $23.64. The stock has a market capitalization of $2.86 billion, a PE ratio of 72.84 and a beta of 0.31. The company has a debt-to-equity ratio of 0.90, a quick ratio of 3.10 and a current ratio of 3.54.

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) last announced its quarterly earnings results on Thursday, October 30th. The company reported $1.67 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.64. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 18.94%. The company had revenue of $458.58 million for the quarter, compared to analyst estimates of $364.58 million. During the same quarter last year, the business earned ($0.46) EPS. Apellis Pharmaceuticals’s revenue for the quarter was up 133.0% on a year-over-year basis. As a group, sell-side analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insiders Place Their Bets

In other Apellis Pharmaceuticals news, insider Pascal Deschatelets sold 5,928 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total transaction of $129,052.56. Following the transaction, the insider directly owned 1,151,382 shares of the company’s stock, valued at $25,065,586.14. The trade was a 0.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Cedric Francois sold 27,192 shares of the business’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total transaction of $591,969.84. Following the transaction, the chief executive officer directly owned 286,045 shares in the company, valued at approximately $6,227,199.65. The trade was a 8.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 125,169 shares of company stock worth $2,700,681. 6.50% of the stock is owned by insiders.

Apellis Pharmaceuticals Profile

(Free Report)

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.

Read More

Want to see what other hedge funds are holding APLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report).